1
|
Kutkat O, Gomaa M, Aboulhoda BE, Moatasim Y, El Taweel A, Kamel MN, El Sayes M, Elkhrsawy A, AbdAllah H, Kandeil A, McKenzie PP, Webby RJ, Ali MA, Kayali G, El-Shesheny R. Genetic and virological characteristics of a reassortant avian influenza A H6N1 virus isolated from wild birds at a live-bird market in Egypt. Arch Virol 2024; 169:95. [PMID: 38594485 DOI: 10.1007/s00705-024-06022-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 02/13/2024] [Indexed: 04/11/2024]
Abstract
The first detection of a human infection with avian influenza A/H6N1 virus in Taiwan in 2013 has raised concerns about this virus. During our routine surveillance of avian influenza viruses (AIVs) in live-bird markets in Egypt, an H6N1 virus was isolated from a garganey duck and was characterized. Phylogenetic analysis indicated that the Egyptian H6N1 strain A/Garganey/Egypt/20869C/2022(H6N1) has a unique genomic constellation, with gene segments inherited from different subtypes (H5N1, H3N8, H7N3, H6N1, and H10N1) that have been detected previously in AIVs from Egypt and some Eurasian countries. We examined the replication of kinetics of this virus in different mammalian cell lines (A549, MDCK, and Vero cells) and compared its pathogenicity to that of the ancestral H6N1 virus A/Quail/HK/421/2002(H6N1). The Egyptian H6N1 virus replicated efficiently in C57BL/6 mice without prior adaptation and grew faster and reached higher titers than in A549 cells than the ancestral strain. These results show that reassortant H6 AIVs might pose a potential threat to human health and highlight the need to continue surveillance of H6 AIVs circulating in nature.
Collapse
Affiliation(s)
- Omnia Kutkat
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Mokhtar Gomaa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Basma Emad Aboulhoda
- Department of Anatomy and Embryology, Faculty of Medicine, Cairo University, Cairo, 11562, Egypt
| | - Yassmin Moatasim
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Mina Nabil Kamel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Mohamed El Sayes
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Amany Elkhrsawy
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Hend AbdAllah
- Department of Anatomy and Embryology, Faculty of Medicine, Cairo University, Cairo, 11562, Egypt
| | - Ahmed Kandeil
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
- Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Pamela P McKenzie
- Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Richard J Webby
- Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Mohamed Ahmed Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | | | - Rabeh El-Shesheny
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt.
| |
Collapse
|
2
|
Gomaa M, Moatasim Y, El Taweel A, Mahmoud SH, El Rifay AS, Kandeil A, McKenzie PP, Webby RJ, El-Shesheny R, Ali MA, Kayali G. We are underestimating, again, the true burden of H5N1 in humans. BMJ Glob Health 2023; 8:e013146. [PMID: 37643809 PMCID: PMC10465887 DOI: 10.1136/bmjgh-2023-013146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Accepted: 08/13/2023] [Indexed: 08/31/2023] Open
Affiliation(s)
- Mokhtar Gomaa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Cairo, Egypt
| | - Yassmin Moatasim
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Cairo, Egypt
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Cairo, Egypt
| | - Sara H Mahmoud
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Cairo, Egypt
| | - Amira S El Rifay
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Cairo, Egypt
| | - Ahmed Kandeil
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Cairo, Egypt
- Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Pamela P McKenzie
- Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Richard J Webby
- Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Rabeh El-Shesheny
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Cairo, Egypt
| | - Mohamed Ahmed Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Cairo, Egypt
| | | |
Collapse
|
3
|
Kayed AE, Kutkat O, Kandeil A, Moatasim Y, El Taweel A, El Sayes M, El-Shesheny R, Aboulhoda BE, Abdeltawab NF, Kayali G, Ali MA, Ramadan MA. Comparative pathogenic potential of avian influenza H7N3 viruses isolated from wild birds in Egypt and their sensitivity to commercial antiviral drugs. Arch Virol 2023; 168:82. [PMID: 36757481 PMCID: PMC9909137 DOI: 10.1007/s00705-022-05646-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Accepted: 11/03/2022] [Indexed: 02/10/2023]
Abstract
Active surveillance and studying the virological features of avian-origin influenza viruses are essential for early warning and preparedness for the next potential pandemic. During our active surveillance of avian influenza viruses in wild birds in Egypt in the period 2014-2017, multiple reassortant low-pathogenic avian influenza H7N3 viruses were isolated. In this study, we investigated and compared the infectivity, pathogenicity, and transmission of four different constellation forms of Egyptian H7N3 viruses in chickens and mice and assessed the sensitivity of these viruses to different commercial antiviral drugs in vitro. Considerable variation in virus pathogenicity was observed in mice infected with different H7N3 viruses. The mortality rate ranged from 20 to 100% in infected mice. Infected chickens showed only ocular clinical signs at three days postinfection as well as systemic viral infection in different organs. Efficient virus replication and transmission in chickens was observed within each group, indicating that these subtypes can spread easily from wild birds to poultry without prior adaptation. Mutations in the viral proteins associated with antiviral drug resistance were not detected, and all strains were sensitive to the antiviral drugs tested. In conclusion, all of the viruses studied had the ability to infect mice and chickens. H7N3 viruses circulating among wild birds in Egypt could threaten poultry production and public health.
Collapse
Affiliation(s)
- Ahmed E Kayed
- Environmental Research Division, Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Omnia Kutkat
- Environmental Research Division, Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Ahmed Kandeil
- Environmental Research Division, Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Yassmin Moatasim
- Environmental Research Division, Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Ahmed El Taweel
- Environmental Research Division, Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Mohamed El Sayes
- Environmental Research Division, Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Rabeh El-Shesheny
- Environmental Research Division, Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt
| | - Basma Emad Aboulhoda
- Department of Anatomy and Embryology, Faculty of Medicine, Cairo University, Cairo, 12613, Egypt
| | - Nourtan F Abdeltawab
- Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, 12613, Egypt
| | | | - Mohamed A Ali
- Environmental Research Division, Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622, Egypt.
| | - Mohammed A Ramadan
- Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, 12613, Egypt.
| |
Collapse
|
4
|
Kamel MN, Mahmoud SH, Moatasim Y, El Taweel A, Shehata M, Shehata MR, AbdElSalam ET, Ali MA, Mostafa A. Immunogenicity and effectiveness of a bivalent influenza A/H1N2 vaccine strain against seasonal human influenza A viruses in mice. J Genet Eng Biotechnol 2022; 20:155. [PMID: 36331680 PMCID: PMC9636361 DOI: 10.1186/s43141-022-00436-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Accepted: 10/23/2022] [Indexed: 11/06/2022]
Abstract
Background Recent studies and reports have documented the ability of the co-circulating seasonal influenza A/H1N1 (ancestor: 2009 pandemic H1N1) and A/H3N2 to exchange their genetic segments, generating a novel H1N2 strain in different geographical localities around the world with an ability to infect human. This raises concerns and triggers alarms to develop a multivalent vaccine that can protect against the documented H1- and H3-type human influenza A viruses (IAVs). Results Here, we generated a PR8-based vaccine strain that carries the HA gene segment from the contemporary H1N1 virus while the NA gene segment was derived from a currently circulating influenza A/H3N2 strain. A recombinant PR8-based H1N2 vaccine strain (rgH1N2), engineered by reassortment between influenza A/H1N1 and A/H3N2 to mimic the documented human influenza A/H1N2, was used for immunization to provoke immunogenicity and cross-antigenicity against the H1- and H3-type human IAVs and was evaluated for its immunogenicity and effectiveness in mice. Following challenge infection of rgH1N2-vaccinated mice with contemporary influenza A/H1N1 and A/H3N2, results revealed that rgH1N2-vaccinated mice showed less viral shedding, more survival, and less body weight loss compared to control unvaccinated groups and vaccinated mice with rgH1N1 and rgH3N2. Conclusions This study highlights the applicability of the PR8-based H1N2 vaccine strain to protect against seasonal IAVs and emphasizes the role of both surface proteins, HA and NA, to stimulate protective and neutralizing antibodies against circulating influenza A/H1N1 and A/H3N2 strains.
Collapse
|
5
|
Youssef MA, Panda SS, Aboshouk DR, Said MF, El Taweel A, GabAllah M, Fayad W, Soliman AF, Mostafa A, Fawzy NG, Girgis AS. Novel Curcumin Mimics: Design, Synthesis, Biological Properties and Computational Studies of Piperidone‐Piperazine Conjugates. ChemistrySelect 2022. [DOI: 10.1002/slct.202201406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M. Adel Youssef
- Department of Chemistry Faculty of Science Helwan University Helwan Egypt
| | - Siva S. Panda
- Department of Chemistry and Physics Augusta University Augusta GA 30912 USA
| | - Dalia R. Aboshouk
- Department of Pesticide Chemistry National Research Centre Dokki Giza 12622 Egypt
| | - Mona F. Said
- Department of Pharmaceutical Chemistry Faculty of Pharmacy Cairo University Cairo 11562 Egypt
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses National Research Centre Dokki Giza 12622 Egypt
| | - Mohamed GabAllah
- Center of Scientific Excellence for Influenza Viruses National Research Centre Dokki Giza 12622 Egypt
| | - Walid Fayad
- Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department National Research Centre Dokki, Giza 12622 Egypt
| | - Ahmed F. Soliman
- Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department National Research Centre Dokki, Giza 12622 Egypt
| | - Ahmed Mostafa
- Center of Scientific Excellence for Influenza Viruses National Research Centre Dokki Giza 12622 Egypt
| | - Nehmedo G. Fawzy
- Department of Pesticide Chemistry National Research Centre Dokki Giza 12622 Egypt
| | - Adel S. Girgis
- Department of Pesticide Chemistry National Research Centre Dokki Giza 12622 Egypt
| |
Collapse
|
6
|
El-Shesheny R, El Taweel A, Gomaa MR, Roshdy WH, Kandeil A, Webby RJ, Kayali G, Ali MA. Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak. Vaccine 2022; 40:4303-4306. [PMID: 35697574 PMCID: PMC9187864 DOI: 10.1016/j.vaccine.2022.05.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 05/10/2022] [Accepted: 05/31/2022] [Indexed: 11/10/2022]
Abstract
The diversity of SARS-CoV-2 continues to lead to the emergence of new SARS-CoV-2 variants. SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic by determining the neutralizing antibody response. This study aims to investigate vaccine-induced antibodies against most common variants of SARS-CoV-2 in Egypt. Sera samples were collected from vaccinated participants and neutralizing activity against the SARS-CoV-2 variants was determined using microneutralization assay. Our results show that the BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCov-19 (AstraZeneca), and Ad26.COV2.S COVID-19 (Janssen) vaccines elicited neutralizing antibody responses more than the BBIBP-CorV vaccine (Sinopharm) against B.1, C.36.3, and AY.32 (Delta) variants. While vaccines remain highly effective in managing the COVID-19 pandemic, ongoing monitoring of vaccine effectiveness is needed.
Collapse
Affiliation(s)
- Rabeh El-Shesheny
- Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt.
| | - Ahmed El Taweel
- Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt.
| | - Mokhtar R Gomaa
- Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt.
| | - Wael H Roshdy
- Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt.
| | - Ahmed Kandeil
- Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38107, USA.
| | - Richard J Webby
- Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38107, USA.
| | | | - Mohamed A Ali
- Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt.
| |
Collapse
|
7
|
Roshdy WH, Kandeil A, El-Shesheny R, Khalifa MK, Al-Karmalawy AA, Showky S, Naguib A, Elguindy N, Fahim M, Abu Elsood H, El Taweel A, Salamony A, Mohsen A, Kayali G, Ali MA, Kandeel A. Insight into Genetic Characteristics of Identified SARS-CoV-2 Variants in Egypt from March 2020 to May 2021. Pathogens 2022; 11:pathogens11080834. [PMID: 35894057 PMCID: PMC9330621 DOI: 10.3390/pathogens11080834] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 06/05/2022] [Accepted: 06/08/2022] [Indexed: 01/01/2023] Open
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first detected in Egypt in February 2020. Data about the prevalence rates of the SARS-CoV-2 lineages are relatively scarce. To understand the genetic characteristics of SARS-CoV-2 in Egypt during several waves of the pandemic, we analyzed sequences of 1256 Egyptian SARS-CoV-2 full genomes from March 2020 to May 2021. From one wave to the next, dominant strains have been observed to be replaced by other dominant strains. We detected an emerging lineage of SARS-CoV-2 in Egypt that shares mutations with the variant of concern (VOC). The neutralizing capacity of sera collected from cases infected with C.36.3 against dominant strains detected in Egypt showed a higher cross reactivity of sera with C.36.3 compared to other strains. Using in silico tools, mutations in the spike of SARS-CoV-2 induced a difference in binding affinity to the viral receptor. The C.36 lineage is the most dominant SARS-CoV-2 lineage in Egypt, and the heterotrophic antigenicity of SARS-CoV-2 variants is asymmetric. These results highlight the value of genetic and antigenic analyses of circulating strains in regions where published sequences are limited.
Collapse
Affiliation(s)
- Wael H. Roshdy
- Central Public Health Laboratory, Ministry of Health and Population, Cairo 11613, Egypt; (M.K.K.); (S.S.); (A.N.); (N.E.); (A.S.)
- Correspondence: (W.H.R.); (M.A.A.)
| | - Ahmed Kandeil
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (R.E.-S.); (A.E.T.)
| | - Rabeh El-Shesheny
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (R.E.-S.); (A.E.T.)
| | - Mohamed K. Khalifa
- Central Public Health Laboratory, Ministry of Health and Population, Cairo 11613, Egypt; (M.K.K.); (S.S.); (A.N.); (N.E.); (A.S.)
| | - Ahmed A. Al-Karmalawy
- Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt;
| | - Shymaa Showky
- Central Public Health Laboratory, Ministry of Health and Population, Cairo 11613, Egypt; (M.K.K.); (S.S.); (A.N.); (N.E.); (A.S.)
| | - Amel Naguib
- Central Public Health Laboratory, Ministry of Health and Population, Cairo 11613, Egypt; (M.K.K.); (S.S.); (A.N.); (N.E.); (A.S.)
| | - Nancy Elguindy
- Central Public Health Laboratory, Ministry of Health and Population, Cairo 11613, Egypt; (M.K.K.); (S.S.); (A.N.); (N.E.); (A.S.)
| | - Manal Fahim
- Department of Surveillance and Epidemiology, Ministry of Health and Population, Cairo 11613, Egypt; (M.F.); (H.A.E.)
| | - Hanaa Abu Elsood
- Department of Surveillance and Epidemiology, Ministry of Health and Population, Cairo 11613, Egypt; (M.F.); (H.A.E.)
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (R.E.-S.); (A.E.T.)
| | - Azza Salamony
- Central Public Health Laboratory, Ministry of Health and Population, Cairo 11613, Egypt; (M.K.K.); (S.S.); (A.N.); (N.E.); (A.S.)
| | - Amira Mohsen
- Egypt Country Office, World Health Organization, Cairo 11613, Egypt;
| | | | - Mohamed A. Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (R.E.-S.); (A.E.T.)
- Correspondence: (W.H.R.); (M.A.A.)
| | - Amr Kandeel
- Preventive Sector, Ministry of Health and Population, Cairo 11613, Egypt;
| |
Collapse
|
8
|
Refay ASE, Shehata MA, Sherif LS, Nady HGE, Kholoussi N, Kholoussi S, Baroudy NRE, Gomma MR, Mahmoud SH, Shama NMA, Bagato O, Taweel AE, kandeil A, Ali MA. Prevalence of viral pathogens in a sample of hospitalized Egyptian children with acute lower respiratory tract infections: a two-year prospective study. Bull Natl Res Cent 2022; 46:103. [PMID: 35431533 PMCID: PMC9006499 DOI: 10.1186/s42269-022-00790-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Accepted: 04/02/2022] [Indexed: 06/14/2023]
Abstract
BACKGROUND Viral pneumonias are a major cause of childhood mortality. Proper management needs early and accurate diagnosis. This study objective is to investigate the viral etiologies of pneumonia in children. RESULTS This prospective study enrolled 158 and 101 patients in the first and second year, respectively, and their mean age was 4.72 ± 2.89. Nasopharyngeal swabs were collected and subjected to virus diagnosis by reverse transcription polymerase chain reaction (RT-PCR). Viral etiologies of pneumonia were evidenced in 59.5% of the samples in the first year, all of them were affirmative for influenza A, 2 samples were affirmative for Human coronavirus NL63, and one for Human coronavirus HKU1. In the second year, 87% of patients had a viral illness. The most prevalent agents are human metapneumovirus which was detected in 44 patients (43.6%) followed by human rhinovirus in 35 patients (34.7%) and then parainfluenza-3 viruses in 33 patients (32.7%), while 14 patients had a confirmed diagnosis for both Pan coronavirus and Flu-B virus. CONCLUSIONS Viral infection is prevalent in the childhood period; however, the real magnitude of viral pneumonia in children is underestimated. The reverse transcriptase polymerase chain reaction has to be a vital tool for epidemiological research and is able to clear the gaps in-between clinical pictures and final diagnoses.
Collapse
Affiliation(s)
- Amira S. El Refay
- Child Health Department, National Research Centre, 33 El-Bohouth Street (Former El Tahrir St.), PO Box 12622, Dokki, Giza, Egypt
| | - Manal A. Shehata
- Child Health Department, National Research Centre, 33 El-Bohouth Street (Former El Tahrir St.), PO Box 12622, Dokki, Giza, Egypt
| | - Lobna S. Sherif
- Child Health Department, National Research Centre, 33 El-Bohouth Street (Former El Tahrir St.), PO Box 12622, Dokki, Giza, Egypt
| | - Hala G. El Nady
- Child Health Department, National Research Centre, 33 El-Bohouth Street (Former El Tahrir St.), PO Box 12622, Dokki, Giza, Egypt
| | - Naglaa Kholoussi
- Immunogenetics Department, National Research Centre, Dokki, Egypt
| | - Shams Kholoussi
- Immunogenetics Department, National Research Centre, Dokki, Egypt
| | | | - Mokhtar R. Gomma
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, Egypt
| | - Sara H. Mahmoud
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, Egypt
| | - Noura M. Abo Shama
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, Egypt
| | - Ola Bagato
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, Egypt
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, Egypt
| | - Ahmed kandeil
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, Egypt
| | - Mohamed A. Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, Egypt
| |
Collapse
|
9
|
Kutkat O, Kandeil A, Moatasim Y, Elshaier YAMM, El-Sayed WA, Gaballah ST, El Taweel A, Kamel MN, El Sayes M, Ramadan MA, El-Shesheny R, Abdel-Megeid FME, Webby R, Kayali G, Ali MA. In Vitro and In Vivo Antiviral Studies of New Heteroannulated 1,2,3-Triazole Glycosides Targeting the Neuraminidase of Influenza A Viruses. Pharmaceuticals (Basel) 2022; 15:ph15030351. [PMID: 35337148 PMCID: PMC8950700 DOI: 10.3390/ph15030351] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 02/28/2022] [Accepted: 03/02/2022] [Indexed: 11/16/2022] Open
Abstract
There is an urgent need to develop and synthesize new anti-influenza drugs with activity against different strains, resistance to mutations, and suitability for various populations. Herein, we tested in vitro and in vivo the antiviral activity of new 1,2,3-triazole glycosides incorporating benzimidazole, benzooxazole, or benzotriazole cores synthesized by using a click approach. The Cu-catalyzation strategy consisted of 1,3-dipolar cycloaddition of the azidoalkyl derivative of the respective heterocyclic and different glycosyl acetylenes with five or six carbon sugar moieties. The antiviral activity of the synthesized glycosides against wild-type and neuraminidase inhibitor resistant strains of the avian influenza H5N1 and human influenza H1N1 viruses was high in vitro and in mice. Structure–activity relationship studies showed that varying the glycosyl moiety in the synthesized glycosides enhanced antiviral activity. The compound (2R,3R,4S,5R)-2-((1-(Benzo[d]thiazol-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (Compound 9c) had a 50% inhibitory concentration (IC50) = 2.280 µM and a ligand lipophilic efficiency (LLE) of 6.84. The compound (2R,3R,4S,5R)-2-((1-((1H-Benzo[d]imidazol-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate had IC50 = 2.75 µM and LLE = 7.3 after docking analysis with the H5N1 virus neuraminidase. Compound 9c achieved full protection from H1N1 infection and 80% protection from H5N1 in addition to a high binding energy with neuraminidase and was safe in vitro and in vivo. This compound is suitable for further clinical studies as a new neuraminidase inhibitor.
Collapse
Affiliation(s)
- Omnia Kutkat
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (O.K.); (Y.M.); (A.E.T.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Ahmed Kandeil
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (O.K.); (Y.M.); (A.E.T.); (M.N.K.); (M.E.S.); (R.E.-S.)
- Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA;
- Correspondence: (A.K.); (G.K.); (M.A.A.)
| | - Yassmin Moatasim
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (O.K.); (Y.M.); (A.E.T.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Yaseen A. M. M. Elshaier
- Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City, Menoufia 32897, Egypt;
| | - Wael A. El-Sayed
- Photochemistry Department, National Research Centre, Giza 12622, Egypt; (W.A.E.-S.); (S.T.G.); (F.M.E.A.-M.)
- Department of Chemistry, College of Science, Qassim University, Buraydah 52571, Saudi Arabia
| | - Samir T. Gaballah
- Photochemistry Department, National Research Centre, Giza 12622, Egypt; (W.A.E.-S.); (S.T.G.); (F.M.E.A.-M.)
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (O.K.); (Y.M.); (A.E.T.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Mina Nabil Kamel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (O.K.); (Y.M.); (A.E.T.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Mohamed El Sayes
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (O.K.); (Y.M.); (A.E.T.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Mohammed A. Ramadan
- Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 12613, Egypt;
| | - Rabeh El-Shesheny
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (O.K.); (Y.M.); (A.E.T.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Farouk M. E. Abdel-Megeid
- Photochemistry Department, National Research Centre, Giza 12622, Egypt; (W.A.E.-S.); (S.T.G.); (F.M.E.A.-M.)
| | - Richard Webby
- Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA;
| | - Ghazi Kayali
- Department of Life Sciences, Human Link, Dubai 48800, United Arab Emirates
- Correspondence: (A.K.); (G.K.); (M.A.A.)
| | - Mohamed A. Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (O.K.); (Y.M.); (A.E.T.); (M.N.K.); (M.E.S.); (R.E.-S.)
- Correspondence: (A.K.); (G.K.); (M.A.A.)
| |
Collapse
|
10
|
Kandeil A, Moatasim Y, El Taweel A, El Sayes M, Rubrum A, Jeevan T, McKenzie PP, Webby RJ, Ali MA, Kayali G, El-Shesheny R. Genetic and Antigenic Characteristics of Highly Pathogenic Avian Influenza A(H5N8) Viruses Circulating in Domestic Poultry in Egypt, 2017–2021. Microorganisms 2022; 10:microorganisms10030595. [PMID: 35336170 PMCID: PMC8948635 DOI: 10.3390/microorganisms10030595] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 03/04/2022] [Accepted: 03/07/2022] [Indexed: 02/05/2023] Open
Abstract
In Egypt, the endemicity of avian influenza viruses is a serious concern. Since 2016, several outbreaks of H5N8 have been recorded among domestic poultry in various areas of the country. Active surveillance of domestic poultry across several governorates in Egypt from 2017 to 2021 detected at least six genotypes of Highly Pathogenic Avian Influenza (HPAI) H5N8 viruses with evidence of partial or complete annual replacement of dominant strains. Although all Egyptian H5N8 viruses had clade 2.3.4.4b hemagglutinin (HA) genes, the remaining viral gene segments were from multiple geographic origins, indicating that the H5N8 isolates resulted from multiple introductions. Mutations in the viral proteins associated with pathogenicity and antiviral drug resistance were detected. Some mutations in the HA resulted in antigenic drift. Heterogeneity in circulating H5N8 HPAI threatens poultry production and public health.
Collapse
Affiliation(s)
- Ahmed Kandeil
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (Y.M.); (A.E.T.); (M.E.S.); (M.A.A.)
- Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; (A.R.); (T.J.); (P.P.M.)
| | - Yassmin Moatasim
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (Y.M.); (A.E.T.); (M.E.S.); (M.A.A.)
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (Y.M.); (A.E.T.); (M.E.S.); (M.A.A.)
| | - Mohamed El Sayes
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (Y.M.); (A.E.T.); (M.E.S.); (M.A.A.)
| | - Adam Rubrum
- Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; (A.R.); (T.J.); (P.P.M.)
| | - Trushar Jeevan
- Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; (A.R.); (T.J.); (P.P.M.)
| | - Pamela P. McKenzie
- Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; (A.R.); (T.J.); (P.P.M.)
| | - Richard J. Webby
- Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; (A.R.); (T.J.); (P.P.M.)
- Correspondence: (R.J.W.); (G.K.); (R.E.-S.)
| | - Mohamed A. Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (Y.M.); (A.E.T.); (M.E.S.); (M.A.A.)
| | - Ghazi Kayali
- Human Link, Dubai 971, United Arab Emirates
- Correspondence: (R.J.W.); (G.K.); (R.E.-S.)
| | - Rabeh El-Shesheny
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (Y.M.); (A.E.T.); (M.E.S.); (M.A.A.)
- Correspondence: (R.J.W.); (G.K.); (R.E.-S.)
| |
Collapse
|
11
|
Mahmoud DB, Bakr MM, Al-karmalawy AA, Moatasim Y, El Taweel A, Mostafa A. Scrutinizing the Feasibility of Nonionic Surfactants to Form Isotropic Bicelles of Curcumin: a Potential Antiviral Candidate Against COVID-19. AAPS PharmSciTech 2021; 23:44. [PMID: 34966978 PMCID: PMC8716085 DOI: 10.1208/s12249-021-02197-2] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Accepted: 12/08/2021] [Indexed: 02/07/2023] Open
Abstract
Investigating bicelles as an oral drug delivery system and exploiting their structural benefits can pave the way to formulate hydrophobic drugs and potentiate their activity. Herein, the ability of non-ionic surfactants (labrasol®, tween 80, cremophore EL and pluronic F127) to form curcumin loaded bicelles with phosphatidylcholine, utilizing a simple method, was investigated. Molecular docking was used to understand the mechanism of bicelles formation. The % transmittance and TEM exhibited bicelles formation with labrasol® and tween 80, while cremophor EL and pluronic F127 tended to form mixed micelles. The surfactant-based nanostructures significantly improved curcumin dissolution (99.2 ± 2.6% within 10 min in case of tween 80-based bicelles) compared to liposomes and curcumin suspension in non-sink conditions. The prepared formulations improved curcumin ex vivo permeation over liposomes and drug suspension. Further, the therapeutic antiviral activity of the formulated curcumin against SARS-CoV-2 was potentiated over drug suspension. Although both Labrasol® and tween 80 bicelles could form bicelles and enhance the oral delivery of curcumin when compared to liposomes and drug suspension, the mixed micelles formulations depicted superiority than bicelles formulations. Our findings provide promising formulations that can be utilized for further preclinical and clinical studies of curcumin as an antiviral therapy for COVID-19 patients. Graphical Abstract ![]()
Collapse
|
12
|
Srour AM, Panda SS, Mostafa A, Fayad W, El-Manawaty MA, A. F. Soliman A, Moatasim Y, El Taweel A, Abdelhameed MF, Bekheit MS, Ali MA, Girgis AS. Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties. Bioorg Chem 2021; 117:105466. [PMID: 34775204 PMCID: PMC8566089 DOI: 10.1016/j.bioorg.2021.105466] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Accepted: 10/31/2021] [Indexed: 12/16/2022]
Abstract
Series of piperidone-salicylate conjugates were synthesized through the reaction of 3E,5E-bis(arylidene)-4-piperidones with the appropriate acid chloride of acetylsalicylate in the presence of triethylamine. All the synthesized conjugates reveal antiproliferative properties against A431 (squamous skin) cancer cell line with potency higher than that of 5-fluorouracil. Many of the synthesized agents also exhibit promising antiproliferative properties against HCT116 (colon) cancer cell line, of which 5o and 5c are the most effective with 12.9, 9.8 folds potency compared with Sunitinib. Promising activity is also shown against MCF7 (breast) cancer cell line with 1.19, 1.12 folds relative to 5-fluorouracil. PI-flow cytometry of compound 5c supports the arrest of cell cycle at G1-phase. However, compound 5o and Sunitinib arrest the cell cycle at S-phase. The synthesized conjugates can be considered as multi-targeted tyrosine kinase inhibitors due to the promising properties against VEGFR-2 and EGFR in MCF7 and HCT116. CDOCKER studies support the EGFR inhibitory properties. Compounds 5p and 5i possessing thienylidene heterocycle are anti-SARS-CoV-2 with high therapeutic indices. Many of the synthesized agents show enhanced COX-1/2 properties than aspirin with better selectivity index towards COX-2 relative to COX-1. The possible applicability of the potent candidates discovered as antitumor and anti-SARS-CoV-2 is supported by the safe profile against normal (non-cancer, RPE1 and VERO-E6) cells.
Collapse
Affiliation(s)
- Aladdin M. Srour
- Department of Therapeutic Chemistry, National Research Centre, Dokki, Giza 12622, Egypt
| | - Siva S. Panda
- Department of Chemistry & Physics, Augusta University, Augusta, GA 30912, US
| | - Ahmed Mostafa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt
| | - Walid Fayad
- Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, National Research Centre, Dokki, Giza 12622, Egypt
| | - May A. El-Manawaty
- Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, National Research Centre, Dokki, Giza 12622, Egypt
| | - Ahmed A. F. Soliman
- Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, National Research Centre, Dokki, Giza 12622, Egypt
| | - Yassmin Moatasim
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt
| | | | - Mohamed S. Bekheit
- Department of Pesticide Chemistry, National Research Centre, Dokki, Giza 12622, Egypt
| | - Mohamed A. Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt
| | - Adel S. Girgis
- Department of Pesticide Chemistry, National Research Centre, Dokki, Giza 12622, Egypt,Corresponding author
| |
Collapse
|
13
|
El Rifay AS, Mahmoud SH, Marouf MA, Gomaa MR, El Taweel A, Abo Shama NM, GabAllah M, Abd El Dayem SM, Kandeil A, Mostafa A, El‐Shesheny R, Kayali G, Ali MA. Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt. Influenza Other Respir Viruses 2021; 15:750-756. [PMID: 34264010 PMCID: PMC8446982 DOI: 10.1111/irv.12889] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 06/30/2021] [Accepted: 07/02/2021] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND Reported laboratory-confirmed COVID-19 cases underestimate the true burden of disease as cases without laboratory confirmation, and asymptomatic and mild cases are missed by local surveillance systems. Population-based seroprevalence studies can provide better estimates of burden of disease by taking into account infections that were missed by surveillance systems. Additionally, little is known about the determinants of seroconversion in community settings. METHODS We conducted a cross-sectional serologic survey among 888 participants in Egypt. RESULTS Neutralizing antibodies were detected in 30% of study volunteers. Age and educational level were associated with being seropositive as people older than 70 years and people with graduate degrees had lower seroprevalence. Self-reporting cases having COVID-19-related symptoms such as fever, malaise, headache, dyspnea, dry cough, chest pain, diarrhea, and loss of taste or smell were all associated with having antibodies. Fever and loss of taste or smell were strong predictors with odds ratios of 2.1 (95% confidence interval: 1.3-3.5) and 4.5 (95% confidence interval: 2.6-7.8), respectively. CONCLUSIONS Our results can guide COVID-19 prevention and control policies and assist in determining the immunity level in some Egyptian communities.
Collapse
Affiliation(s)
- Amira S. El Rifay
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
- Child Health DepartmentNational Research CentreGizaEgypt
| | - Sara H. Mahmoud
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
| | - Mohamed A. Marouf
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
| | - Mokhtar R. Gomaa
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
| | - Ahmed El Taweel
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
| | - Noura M. Abo Shama
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
| | - Mohamed GabAllah
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
| | | | - Ahmed Kandeil
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
| | - Ahmed Mostafa
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
| | - Rabeh El‐Shesheny
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
| | - Ghazi Kayali
- Department of Epidemiology, Human Genetics, and Environmental SciencesUniversity of TexasHoustonTexasUSA
- Life Sciences DivisionHuman LinkDubaiUnited Arab Emirates
| | - Mohamed A. Ali
- Centre of Scientific Excellence for Influenza VirusesNational Research CentreGizaEgypt
| |
Collapse
|
14
|
Gomaa MR, El Rifay AS, Shehata M, Kandeil A, Nabil Kamel M, Marouf MA, GabAllah M, El Taweel A, Kayed AE, Kutkat O, Moatasim Y, Mahmoud SH, Abo Shama NM, El Sayes M, Mostafa A, El-Shesheny R, McKenzie PP, Webby RJ, Kayali G, Ali MA. Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort. PLoS Pathog 2021; 17:e1009413. [PMID: 33705496 PMCID: PMC7987187 DOI: 10.1371/journal.ppat.1009413] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 03/23/2021] [Accepted: 02/22/2021] [Indexed: 12/19/2022] Open
Abstract
SARS-CoV-2 virus is transmitted in closed settings to people in contact with COVID-19 patients such as healthcare workers and household contacts. However, household person-to-person transmission studies are limited. Households participating in an ongoing cohort study of influenza incidence and prevalence in rural Egypt were followed. Baseline enrollment was done from August 2015 to March 2017. The study protocol was amended in April 2020 to allow COVID-19 incidence and seroprevalence studies. A total of 290 households including 1598 participants were enrolled and followed from April to October 2020 in four study sites. When a participant showed respiratory illness symptoms, a serum sample and a nasal and an oropharyngeal swab were obtained. Swabs were tested by RT-PCR for SARS-CoV-2 infection. If positive, the subject was followed and swabs collected on days three, six, nine, and 14 after the first swab day and a serum sample obtained on day 14. All subjects residing with the index case were swabbed following the same sampling schedule. Sera were collected from cohort participants in October 2020 to assess seroprevalence. Swabs were tested by RT-PCR. Sera were tested by Microneutralization Assay to measure the neutralizing antibody titer. Incidence of COVID-19, household secondary attack rate, and seroprevalence in the cohort were determined. The incidence of COVID-19 was 6.9% and the household secondary attack rate was 89.8%. Transmission within households occurred within two-days of confirming the index case. Infections were asymptomatic or mild with symptoms resolving within 10 days. The majority developed a neutralizing antibody titer by day 14 post onset. The overall seroprevalence among cohort participants was 34.8%. These results suggest that within-household transmission is high in Egypt. Asymptomatic or mild illness is common. Most infections seroconvert and have a durable neutralizing antibody titer.
Collapse
Affiliation(s)
- Mokhtar R. Gomaa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Amira S. El Rifay
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Mahmoud Shehata
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Ahmed Kandeil
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Mina Nabil Kamel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Mohamed A. Marouf
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Mohamed GabAllah
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Ahmed E. Kayed
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Omnia Kutkat
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Yassmin Moatasim
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Sara H. Mahmoud
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Noura M. Abo Shama
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Mohamed El Sayes
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Ahmed Mostafa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Rabeh El-Shesheny
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Pamela P. McKenzie
- Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Richard J. Webby
- Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Ghazi Kayali
- Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, Texas, United States of America
- Human Link, Dubai, United Arab Emirates
| | - Mohamed A. Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| |
Collapse
|
15
|
Mostafa A, Kandeil A, A. M. M. Elshaier Y, Kutkat O, Moatasim Y, Rashad AA, Shehata M, Gomaa MR, Mahrous N, Mahmoud SH, GabAllah M, Abbas H, Taweel AE, Kayed AE, Kamel MN, Sayes ME, Mahmoud DB, El-Shesheny R, Kayali G, Ali MA. FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. Pharmaceuticals (Basel) 2020; 13:E443. [PMID: 33291642 PMCID: PMC7761982 DOI: 10.3390/ph13120443] [Citation(s) in RCA: 91] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 11/30/2020] [Accepted: 12/01/2020] [Indexed: 12/16/2022] Open
Abstract
(1) Background: Drug repositioning is an unconventional drug discovery approach to explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to alleviate the COVID-19 pandemic disease. (2) Methods: Herein, we tested the antiviral activity of anti-microbial and anti-inflammatory Food and Drug Administration (FDA)-approved drugs, commonly prescribed to relieve respiratory symptoms, against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the viral causative agent of the COVID-19 pandemic. (3) Results: Of these FDA-approved antimicrobial drugs, Azithromycin, Niclosamide, and Nitazoxanide showed a promising ability to hinder the replication of a SARS-CoV-2 isolate, with IC50 of 0.32, 0.16, and 1.29 µM, respectively. We provided evidence that several antihistamine and anti-inflammatory drugs could partially reduce SARS-CoV-2 replication in vitro. Furthermore, this study showed that Azithromycin can selectively impair SARS-CoV-2 replication, but not the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). A virtual screening study illustrated that Azithromycin, Niclosamide, and Nitazoxanide bind to the main protease of SARS-CoV-2 (Protein data bank (PDB) ID: 6lu7) in binding mode similar to the reported co-crystalized ligand. Also, Niclosamide displayed hydrogen bond (HB) interaction with the key peptide moiety GLN: 493A of the spike glycoprotein active site. (4) Conclusions: The results suggest that Piroxicam should be prescribed in combination with Azithromycin for COVID-19 patients.
Collapse
Affiliation(s)
- Ahmed Mostafa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Ahmed Kandeil
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Yaseen A. M. M. Elshaier
- Organic & Medicinal Chemistry Department, Faculty of Pharmacy, University of Sadat City, Menoufia 32897, Egypt;
| | - Omnia Kutkat
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Yassmin Moatasim
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Adel A. Rashad
- Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, USA;
| | - Mahmoud Shehata
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Mokhtar R. Gomaa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Noura Mahrous
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Sara H. Mahmoud
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Mohamed GabAllah
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Hisham Abbas
- Department of Microbiology and Immunology, Zagazig University, Zagazig 44519, Egypt;
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Ahmed E. Kayed
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Mina Nabil Kamel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Mohamed El Sayes
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Dina B. Mahmoud
- Pharmaceutics Department, National Organization for Drug Control and Research, Giza 12654, Egypt;
| | - Rabeh El-Shesheny
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| | - Ghazi Kayali
- Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030, USA
- Human Link, Baabda 1109, Lebanon
| | - Mohamed A. Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; (A.K.); (O.K.); (Y.M.); (M.S.); (M.R.G.); (N.M.); (S.H.M.); (M.G.); (A.E.T.); (A.E.K.); (M.N.K.); (M.E.S.); (R.E.-S.)
| |
Collapse
|
16
|
Gomaa MR, Kandeil A, Mostafa A, Roshdy WH, Kayed AE, Shehata M, Kutkat O, Moatasim Y, El Taweel A, Mahmoud SH, Kamel MN, Abo Shama NM, El Sayes M, El-Shesheny R, Bakheet OH, Elgohary MA, Elbadry M, Nassif NN, Ahmed SH, Abdel Messih IY, Kayali G, Ali MA. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors. Front Microbiol 2020; 11:596851. [PMID: 33329484 PMCID: PMC7732494 DOI: 10.3389/fmicb.2020.596851] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Accepted: 11/04/2020] [Indexed: 12/20/2022] Open
Abstract
Using convalescent plasma as immunotherapy is an old method for treatment of infectious diseases. Several countries have recently allowed the use of such therapy for the treatment of COVID-19 patients especially those who are critically ill. A similar program is currently being tested in Egypt. Here, we tested 227 plasma samples from convalescent donors in Egypt for neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using a microneutralization (MN) assay. A third of the tested samples did not have antibody titers and 58% had titers between 1:10 and 1:80. Only 12% had titers >1:160. We also compared MN assays using different virus concentrations, plaque reduction neutralization (PRNT) assays, and a chemiluminescence assay that measures immunoglobulin G (IgG) binding to N and S proteins of SARS-CoV-2. Our results indicated that a MN assay using 100 TCID50/ml provides comparable results to PRNT and allows for high throughput testing.
Collapse
Affiliation(s)
- Mokhtar R Gomaa
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Ahmed Kandeil
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Ahmed Mostafa
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Wael H Roshdy
- Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt
| | - Ahmed E Kayed
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Mahmoud Shehata
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Omnia Kutkat
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Yassmin Moatasim
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Sara H Mahmoud
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Mina Nabil Kamel
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Noura M Abo Shama
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Mohamed El Sayes
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Rabeh El-Shesheny
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| | - Osama H Bakheet
- Department of Clinical Pathology, Military Medical Academy, Cairo, Egypt
| | | | - Mohamed Elbadry
- Tropical Medicine and Gastroenterology Department, Aswan University, Aswan, Egypt
| | - Naguib N Nassif
- Preventive Medicine Department, Aswan Health Affairs Directorate, Aswan, Egypt
| | - Salwa H Ahmed
- Clinical Pharmacology Department, Aswan Fever Hospital, Aswan, Egypt
| | | | - Ghazi Kayali
- Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, Texas, TX, United States.,Human Link, Baabda, Lebanon
| | - Mohamed A Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Center, Giza, Egypt
| |
Collapse
|
17
|
Kandeil A, Gomaa MR, El Taweel A, Mostafa A, Shehata M, Kayed AE, Kutkat O, Moatasim Y, Mahmoud SH, Kamel MN, Shama NMA, El Sayes M, El-Shesheny R, Yassien MA, Webby RJ, Kayali G, Ali MA. Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2. PLoS One 2020; 15:e0241471. [PMID: 33112930 PMCID: PMC7592750 DOI: 10.1371/journal.pone.0241471] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Accepted: 10/15/2020] [Indexed: 12/18/2022] Open
Abstract
Anecdotal evidence showed a negative correlation between Bacille Calmette-Guérin (BCG) vaccination and incidence of COVID-19. Incidence of the disease in children is much lower than in adults. It is hypothesized that BCG and other childhood vaccinations may provide some protection against SARS-CoV-2 infection through trained or adaptive immune responses. Here, we tested whether BCG, Pneumococcal, Rotavirus, Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae, Hepatitis B, Meningococcal, Measles, Mumps, and Rubella vaccines provide cross-reactive neutralizing antibodies against SARS-CoV-2 in BALB/c mice. Results indicated that none of these vaccines provided antibodies capable of neutralizing SARS-CoV-2 up to seven weeks post vaccination. We conclude that if such vaccines have any role in COVID-19 immunity, this role is not antibody-mediated.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Animals
- Antibodies, Neutralizing/biosynthesis
- Antibodies, Neutralizing/blood
- Antibodies, Viral/biosynthesis
- Antibodies, Viral/blood
- Betacoronavirus/immunology
- COVID-19
- Child
- Child, Preschool
- Coronavirus Infections/immunology
- Coronavirus Infections/prevention & control
- Cross Reactions
- Female
- Humans
- Immune Sera/immunology
- Immunogenicity, Vaccine
- Mice
- Mice, Inbred BALB C
- Middle Aged
- Neutralization Tests
- Pandemics/prevention & control
- Pneumonia, Viral/immunology
- Pneumonia, Viral/prevention & control
- SARS-CoV-2
- Vaccination
- Vaccines/immunology
- Vaccines, Inactivated/immunology
- Viral Vaccines/immunology
- Young Adult
Collapse
Affiliation(s)
- Ahmed Kandeil
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Mokhtar R. Gomaa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Ahmed El Taweel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Ahmed Mostafa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Mahmoud Shehata
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Ahmed E. Kayed
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Omnia Kutkat
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Yassmin Moatasim
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Sara H. Mahmoud
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Mina Nabil Kamel
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Noura M. Abo Shama
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Mohamed El Sayes
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | - Rabeh El-Shesheny
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| | | | - Richard J. Webby
- Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Ghazi Kayali
- Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, Texas, United States of America
- Human Link, Hazmieh, Baabda, Lebanon
| | - Mohamed A. Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt
| |
Collapse
|
18
|
El Taweel A, Kandeil A, Barakat A, Alfaroq Rabiee O, Kayali G, Ali MA. Diversity of Astroviruses Circulating in Humans, Bats, and Wild Birds in Egypt. Viruses 2020; 12:v12050485. [PMID: 32357556 PMCID: PMC7290939 DOI: 10.3390/v12050485] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 04/17/2020] [Accepted: 04/24/2020] [Indexed: 01/14/2023] Open
Abstract
Astroviruses belong to Astroviridae family which includes two main genera: Mamastroviruses that infect mammals, and Avastroviruses that infect avian hosts. Bats and wild birds are considered among the natural reservoirs for astroviruses. Infections in humans are associated with severe gastroenteritis, especially among children. We conducted surveillance for astroviruses in bats, wild birds, and humans in Egypt. Our results indicated relatively high prevalence of astroviruses in those hosts. Phylogenetic analysis revealed diversity of these viruses within hosts. Detected human viruses showed similarity with classic and variant human astroviruses, as well as similarity with animal-origin viruses. Viruses in bats were dispersed, with similarities to other bat viruses as well as other mammalian, including human, viruses. Wild bird viruses varied and were related to other avastroviruses, as well as human astroviruses. Our results indicate that astroviruses are common in bats, wild birds, and humans in Egypt, with a wide gene pool. Potential cross-species transmission may be occurring but should be verified by further surveillance and molecular studies.
Collapse
Affiliation(s)
- Ahmed El Taweel
- Center of Scientific Excellence for Influenza Virus, Environmental Research Division, National Research Centre, El-Buhouth Street, Dokki, Giza 12311, Egypt; (A.E.T.); (A.K.)
| | - Ahmed Kandeil
- Center of Scientific Excellence for Influenza Virus, Environmental Research Division, National Research Centre, El-Buhouth Street, Dokki, Giza 12311, Egypt; (A.E.T.); (A.K.)
| | - Ahmed Barakat
- Microbiology Department, Faculty of Science, Ain Shams University, Cairo 11566, Egypt; (A.B.); (O.A.R.)
| | - Omar Alfaroq Rabiee
- Microbiology Department, Faculty of Science, Ain Shams University, Cairo 11566, Egypt; (A.B.); (O.A.R.)
| | - Ghazi Kayali
- Human Link, Hazmieh 1109, Lebanon
- Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030, USA
- Correspondence: (G.K.); (M.A.A.); Tel.: +961-545-4252 (G.K.); +20-100-191-6410 (M.A.A.); Fax: +961-545-8045 (G.K.); +20-237-481-483 (M.A.A.)
| | - Mohamed Ahmed Ali
- Center of Scientific Excellence for Influenza Virus, Environmental Research Division, National Research Centre, El-Buhouth Street, Dokki, Giza 12311, Egypt; (A.E.T.); (A.K.)
- Correspondence: (G.K.); (M.A.A.); Tel.: +961-545-4252 (G.K.); +20-100-191-6410 (M.A.A.); Fax: +961-545-8045 (G.K.); +20-237-481-483 (M.A.A.)
| |
Collapse
|